<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940106-2-00052</title>
	</head>
	<body>
		<main>
			<p><!-- PJG ITAG l=10 g=1 f=2 --> DATES: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Submit written comments by April 6, 1994. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> <!-- PJG STAG 4703 -->  <!-- PJG ITAG l=69 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=41 g=1 f=1 -->  <RINDOCK>[Docket No. 93D&hyph;0398] </RINDOCK> <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=52 g=1 f=1 -->  <DOCTITLE>Proposed Guideline Regarding Microbiological Testing for Antimicrobial Food-Animal Drugs; Availability </DOCTITLE> <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <AGENCY> <!-- PJG ITAG l=10 g=1 f=2 --> AGENCY: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Food and Drug Administration, HHS. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> </AGENCY> <ACTION> <!-- PJG ITAG l=10 g=1 f=2 --> ACTION: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Notice. <!-- PJG /ITAG -->  <!-- PJG ITAG l=59 g=1 f=1 -->   <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </ACTION> <SUMMARY> <!-- PJG ITAG l=10 g=1 f=2 --> SUMMARY: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  The Food and Drug Administration (FDA) is announcing the availability of a proposed guideline entitled ``Microbiological Testing of Antimicrobial Drug Residues in Food'' prepared by the Center for Veterinary Medicine (CVM) regarding the tests required for food-animal antimicrobial drug products to establish their human-food safety. This proposed guideline provides criteria for determining which antimicrobials will require supplemental testing, and recommends test procedures that are necessary to ensure that antimicrobial residues will not cause intestinal microflora perturbations in the consumer.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->   <!-- PJG 0012 frnewline --> </SUMMARY> <DATE> <!-- PJG ITAG l=10 g=1 f=2 --> DATES: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Submit written comments by April 6, 1994. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </DATE> <ADDRESS> <!-- PJG ITAG l=10 g=1 f=2 --> ADDRESSES: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Submit written requests for single copies of the proposed guideline to the Communications and Education Branch (HFV&hyph;12), Center for Veterinary Medicine, Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301&hyph;594&hyph;1755, or the contact person (address below). Send two self-addressed adhesive labels to assist that office in processing your requests. Submit written comments on the proposed guideline to the Dockets Management Branch (HFA&hyph;305), Food and Drug Administration, rm. 1&hyph;23, 12420 Parklawn Dr., Rockville, MD 20857. Requests and comments should be identified with the docket number found in brackets in the heading of this document. A copy of the proposed guideline and received comments are available for public examination in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </ADDRESS> <FURTHER> <!-- PJG ITAG l=10 g=1 f=2 --> FOR FURTHER INFORMATION CONTACT: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Haydee Fernandez, Center for Veterinary Medicine (HFV&hyph;154), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301&hyph;594&hyph;1684. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </FURTHER> <SUPPLEM> <!-- PJG ITAG l=10 g=1 f=2 --> SUPPLEMENTARY INFORMATION: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  FDA is announcing the availability of a proposed guideline entitled ``Microbiological Testing of Antimicrobial Drug Residues in Food'' regarding required testing for food-animal antimicrobial drug products. In evaluating new animal drug applications (NADA's) the agency must determine, among other factors, the safety of the intended use of the drug, including the cumulative effect on man or animal required by section 512(d)(2)(B) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 360b(d)(2)(B)). The proposed guideline provides criteria that will be used to determine which antimicrobial drugs will require supplemental testing to ensure that antimicrobial residues will not cause intestinal microflora perturbations in the consumer exposed to antimicrobial residues. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  It is well known that therapeutic doses of antibiotics can cause adverse effects on the intestinal microflora ecology. In most cases the lowest dose at which these perturbations occur have not been determined; however, CVM believes that the ecology of the human intestinal microflora should not be disturbed by the residues of antimicrobials used in food-animals.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  In June 1992, CVM sponsored a symposium on the Microbiological Significance of Drug Residues in Food to evaluate scientific expertise in this area. Information discussed at the symposium reaffirmed CVM's conclusion that the residue antimicrobial activity is a valid endpoint for establishing residue tolerances for antimicrobial animal drugs.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  CVM proposes establishing two categories for antimicrobial drugs: (1) ``New Animal Antimicrobial Drugs Requiring Additional Human Food Safety Microbiological Testing'' and (2) ``New Animal Antimicrobial Drugs Exempt from Additional Human Food Safety Microbiological Testing.'' To qualify for exemption from additional microbiological testing, the antimicrobial drug must have either: (1) ``Very low'' residue levels, (2) residues with limited antimicrobial activity, or (3) no adverse effects on intestinal microflora at approved dosages. Antimicrobial drugs will require additional testing in cases where a safe residue concentration retains antimicrobial activity in humans at residue exposure levels greater than 1 part per million in the total diet. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  CVM requests comments regarding how the proposed guideline should relate the effects of low doses of antibiotics observed in model systems to potential adverse biological effects in humans. In addition, information is requested on the appropriate endpoints for monitoring the effects of the different classes of antibiotics. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  Interested persons may, on or before April 6, 1994, submit to the Dockets Management Branch (address above) written comments on the proposed guideline. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. The proposed guideline and received comments may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 --> Dated: December 28, 1993. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SUPPLEM> <SIGNER> <!-- PJG ITAG l=06 g=1 f=1 --> William K. Hubbard, <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNER> <SIGNJOB> <!-- PJG ITAG l=04 g=1 f=1 --> Acting Deputy Commissioner for Policy. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNJOB> <FRFILING> <!-- PJG ITAG l=40 g=1 f=1 --> [FR Doc. 94&hyph;114 Filed 1&hyph;5&hyph;94; 8:45 am] <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FRFILING> <BILLING> <!-- PJG ITAG l=68 g=1 f=1 --> BILLING CODE 4160&hyph;01&hyph;F <!-- PJG /ITAG --> </BILLING>  <!-- PJG 0012 frnewline -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            